NASDAQ · INDP
Indaptus Therapeutics, Inc.
$3.34+$0.01 (+0.3%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.96% below the high.
Loading market information…
NASDAQ · REVB · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Revelation Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Revelation Biosciences, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$6.16. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Revelation Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 20, 2025 |
| -$59.76-1,137.27% vs estimate |
| $0.00 |
| Q3 2024 | Nov 8, 2024 | -$5.88+70.42% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.34+$0.01 (+0.3%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.96% below the high.
$5.60+$0.09 (+1.63%)
GT Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.52% below the high.
$0.84+$0.19 (+29.23%)
Salarius Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.41% below the high.
$0.76-$0.15 (-16.31%)
Azitra, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.08% below the high.
$0.59-$0.01 (-1.99%)
Onconetix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.71% below the high.
$0.01$0.00 (0.0%)
NKGen Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.56% below the high.
$0.38$0.00 (0.0%)
Avenue Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.8% below the high.
$0.71-$0.12 (-14.18%)
SciSparc Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.69% below the high.
